We thank the BMJ for their generous sharing policies during these unprecedented times. In the below article, Peter Doshi, associate editor of the BMJ, explains how COVID-19 trials are designed, and why they won’t provide the answers needed to show effectiveness or safety.
The recovery data clearly shows vaccines targeting SARS-COV-2 are not necessary. When an infection has 99.9+% recovery rates for the vast majority of the population, treatments are the ethical tools for public health to support.
Loading…
Reload document 
Open in new tab 
